Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

23.88
+0.37001.57%
Pre-market: 23.980.1035+0.43%07:26 EDT
Volume:2.49M
Turnover:59.34M
Market Cap:4.04B
PE:-28.43
High:24.36
Open:23.95
Low:23.48
Close:23.51
52wk High:34.39
52wk Low:6.25
Shares:169.00M
Float Shares:142.96M
Volume Ratio:1.27
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.94
PE(LYR):-27.31

Loading ...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story

Simply Wall St.
·
Apr 29

Tango Therapeutics Inc : Stifel Raises Target Price to $40 From $24

THOMSON REUTERS
·
Apr 27

Tango Therapeutics CFO Matthew Gall files initial beneficial ownership statement

Reuters
·
Apr 25

Tango Therapeutics announces annual shareholder meeting

Reuters
·
Apr 17

Tango Therapeutics President R&D Crystal Adam sells 38,460 shares for $961,500

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman

Reuters
·
Apr 15

Tango Therapeutics Inc - Appoints Matthew Gall as CFO Effective April 15 Succeeding Daniella Beckman

THOMSON REUTERS
·
Apr 15

Press Release: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Dow Jones
·
Apr 15

Tango Therapeutics President, R&D Crystal Adam disposes $0.6 million common shares

Reuters
·
Apr 03

Tango Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Apr 02

Tango Therapeutics; President, R&D Crystal Adam disposes of 12,000 common shares valued at $241,320

Reuters
·
Mar 28

Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)

TIPRANKS
·
Mar 27

Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple

Simply Wall St.
·
Mar 24

Guggenheim Sticks to Their Buy Rating for Tango Therapeutics (TNGX)

TIPRANKS
·
Mar 17

Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn?

Simply Wall St.
·
Mar 17

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Tango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers

Reuters
·
Mar 07

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cooper Co (COO) and CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
Mar 06